895 resultados para Trials (Libel)
Resumo:
Mode of access: Internet.
Resumo:
Errata slip inserted.
Resumo:
Not in Rosenbach, A.S.W. Amer. Jewish bib. and supplements.
Resumo:
At head of title: (From the Concord (Middlesex) Gazette.).
Resumo:
"October term, 1828."
Resumo:
Mode of access: Internet.
Resumo:
Mode of access: Internet.
Resumo:
Contains notes on cases before the Supreme Court in Lennox and Worcester, Massachusetts relating to counterfeiting, libel, and fraud.
Resumo:
Notes on various cases, including cases of burglary, debt, fraud, libel, receiving stolen goods, and one case of attempted murder of an infant by his mother.
Resumo:
Mode of access: Internet.
Resumo:
Mode of access: Internet.
Resumo:
In: The Trials with the defences at large of Mrs. Jane Carlile. London : R. Carlile, 1825.
Resumo:
"From the third New-York edition."
Resumo:
Mode of access: Internet.
Resumo:
Phase I trials use a small number of patients to define a maximum tolerated dose (MTD) and the safety of new agents. We compared data from phase I and registration trials to determine whether early trials predicted later safety and final dose. We searched the U.S. Food and Drug Administration (FDA) website for drugs approved in nonpediatric cancers (January 1990-October 2012). The recommended phase II dose (R2PD) and toxicities from phase I were compared with doses and safety in later trials. In 62 of 85 (73%) matched trials, the dose from the later trial was within 20% of the RP2D. In a multivariable analysis, phase I trials of targeted agents were less predictive of the final approved dose (OR, 0.2 for adopting ± 20% of the RP2D for targeted vs. other classes; P = 0.025). Of the 530 clinically relevant toxicities in later trials, 70% (n = 374) were described in phase I. A significant relationship (P = 0.0032) between increasing the number of patients in phase I (up to 60) and the ability to describe future clinically relevant toxicities was observed. Among 28,505 patients in later trials, the death rate that was related to drug was 1.41%. In conclusion, dosing based on phase I trials was associated with a low toxicity-related death rate in later trials. The ability to predict relevant toxicities correlates with the number of patients on the initial phase I trial. The final dose approved was within 20% of the RP2D in 73% of assessed trials.